



**Supplementary Figure 2 – In vitro characterization of and therapy study with XE-mIL12.** a) cloning scheme of XE-mIL12. b) expected protein structure, yield of TGE in CHO-S cells and expected molecular weight. c) SDS-PAGE analysis (kDa: marker in kDa, nr: non-reduced, r: reduced). d) Size exclusion profile and standard proteins indicated by black arrows (1: IgG, 145 kDa, 2: BSA, 67 kDa, 3: Diabody, 25 kDa). e) MS profile. f) BALB/c mice bearing CT26 tumors transfected with human CAIX received three injections every 72 hours of either PBS as control or 12  $\mu$ g of XE-mIL12. Statistical significance towards PBS control group is shown on day 19, \* $p < 0.05$ . g) Body weight change during the treatment phase.